WHO Drug Information articles from March 1999

WHO Drug Information archives from March 1999

General Policy Issues.(Statistical Data Included)
March 22, 1999... WHO roundtable with the International Generic Pharmaceutical Alliance On 11 February 1999, Dr Gro Harlem Brundtland, the Director-General of WHO, met with some key figures of the generic pharmaceutical industry to explore ways in which...

Reports on Individual Drugs.(Statistical Data Included)
March 22, 1999... Short-course zidovudine in perinatal HIV transmission: more evidence and debate The results of two clinical trials in Thailand and in the USA which documented a 50-68% relative efficacy of short-course zidovudine in prevention of perinatal...

Current Topics.(Statistical Data Included)
March 22, 1999... Ninth International Conference of Drug Regulatory Authorities The Ninth International Conference of Drug Regulatory Authorities (ICDRA) took place from 26-29 April in Berlin, Germany, where 280 participants were welcomed from over 90...

Biomedicines and Vaccines.(Statistical Data Included)
March 22, 1999... Biomedicines: meeting the challenges Norma Morris, University College, London, United Kingdom Over the past two decades, the pace of development of biomedicines has accelerated. With concurrent political and socioeconomic changes, this...

Regulatory Matters.(Statistical Data Included)
March 22, 1999... Losartan and irbesartan: similar in advantage to ACE inhibitors Australia -- The Adverse Drug Reaction Advisory Committee (ADRAC) has reviewed reports associated with the angiotensin II receptor antagonists losartan and irbesartan since...

ATC/DDD Classification (Final).(Statistical Data Included)
March 22, 1999... The following classifications were agreed at a meeting of the WHO International Drug Utilization Working Group which took place on 12-14 October 1998. They came into force on 15 April 1999. All requests for classification should be forwarded to...

ATC/DDD Classification (temporary).(Statistical Data Included)
March 22, 1999... The following temporary classifications were agreed at a meeting of the WHO International Working Group for Drug Statistics Methodology which took place on 13 and 14 May 1999. Comments on or objections to the classification should be forwarded...

Essential Drugs.(Statistical Data Included)
March 22, 1999... WHO Model Formulary As described in previous issues of this journal, work is now under way on the WHO Model Formulary and draft texts will be published regularly to obtain comments on the material proposed for publication. Observations...

International Nonproprietary Names for Pharmaceutical Substances (INN).(Brief Article)
March 22, 1999... Notice is hereby given that, in accordance with article 3 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances, the names given in the list on the following pages are under...

Denominations communes internationales des Substances pharmaceutiques (DCI).(Brief Article)
March 22, 1999... II est notifie que, conformement aux dispositions de article 3 de la Procedure suivre en vue du choix de Denominations communes internationales recommandees pour les Substances pharmaceutiques les denominations ci-dessous sont mises l'etude par...

Denominaciones Comunes Internacionales para las Sustancias Farmaceuticas (DCI).(Brief Article)
March 22, 1999... De conformidad con lo que dispone el parrafo 3 del "Procedimiento de Seleccion de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmaceuticas", se comunica por el presente anuncio que las denominaciones detalladas en...

PROCEDURE FOR THE SELECTION OF RECOMMENDED INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES [*].(Brief Article)
March 22, 1999... The following procedure shall be followed by the World Health Organization in the selection of recommended international nonproprietary names for pharmaceutical substances, in accordance with the World Health Assembly resolution WHA3. 11: ...

GENERAL PRINCIPLES FOR GUIDANCE IN DEVISING INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES[*].
March 22, 1999... 1. International Nonproprietary Names (INN) should be distinctive in sound and spelling. They should not be inconveniently long and should not be liable to confusion with names in common use. 2. The INN for a substance belonging to a group...

PROCEDURE A SUIVRE EN VUE DU CHOIX DE DENOMINATIONS COMMUNES INTERNATIONALES RECOMMANDEES POUR LES SUBSTANCES PHARMACEUTIQUES [*].
March 22, 1999... L'Organisation mondiale de Ia Sante observe Ia procedure exposee ci-dessous pour 'attribution de denominations communes intemationales recommandees pour les substances pharmaceutiques, conformement Ala resolution WHA3.11 de I'Assemblee mondiale...

DIRECTIVES GENERALES POUR LA FORMATION DE DENOMINATIONS COMMUNES INTERNATIONALES APPLICABLES AUX SUBSTANCES PHARMACEUTIQUES [*].
March 22, 1999... 1. Les denominations communes internationales (DCI) devrontse distinguer les unes des autres par leur consonance at leur orthographe. Elles ne devront pas etre d'une Iongueur excessive, ni preter confusion avec des appellations deja couramment...

PROCEDIMIENTO DE SELECCION DE DENOMINACIONES COMUNES INTERNACIONALES RECOMENDADAS PARA LAS SUSTANCIAS FARMACEUTICAS [*].(Brief Article)
March 22, 1999... La Organizacion Mundial de a Salud seguira el procedimiento que se expone a continuacion para la seleccion de denominaciones comunes internacionales recomendadas para las sustancias farmaceuticas, de conformidad con lo dispuesto en la...

PRINCIPIOS GENERALES DE ORIENTACION PARA FORMAR DENOMINACIONES COMUNES INTERNACIONALES PARA SUSTANCIAS FARMACEUTICAS [*].
March 22, 1999... 1. Las Denominaciones Comunes Internacionales (DCI) deberan diferenciarse tanto fonetica come ortograficamente. No deberan ser incomodamente largas, ni dar lugar a confusion con denominaciones de uso comun. 2. La DCI de una sustancia que...